11C-methionine PET for the diagnosis and management of recurrent pituitary adenomas

Tang, Bich-Ngoc-Thanh; Levivier, Marc; Heureux, M.; Wikler, David; Massager, Nicolas; Devriendt, Daniel; David, Philippe; Dumarey, Nicolas; Corvilain, Bernard; Goldman, Serge

doi:10.1007/s00259-005-1882-0

Cited by 57 publications

(63 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Tsuyuguchi et al [157] and Tang et al [158] have performed comparisons in recurrent brain metastasis and pituitary adenomas and found that MET was useful in differentiating recurrent tumor from radiation injury. Overall, in spite of few and small-sized studies and absence of histopathological confirmation in many instances, there is evidence that METYPET has a high sensitivity for detecting tumor recurrences.…”

Section: Differentiation Of Tumor Recurrence Versus Radiation Injurymentioning

confidence: 98%

11C-l-Methionine Positron Emission Tomography in the Clinical Management of Cerebral Gliomas

et al. 2007

View full text Add to dashboard Cite

Positron emission tomography (PET) using L-[methyl-(11)C]-methionine (MET) is the most popular amino acid imaging modality in oncology, although its use is restricted to PET centers with an in-house cyclotron facility. This review focuses on the role of MET-PET in imaging of cerebral gliomas. The biological background of tumor imaging with methionine is discussed with particular emphasis on cellular amino acid transport, amino acid utilization in brain, normal metabolism of methionine, and its alterations in cancer. The role of MET-PET in clinical management of cerebral gliomas in initial diagnosis, differentiation of tumor recurrence from radiation injury, grading, prognostication, tumor-extent delineation, biopsy planning, surgical resection and radiotherapy planning, and assessment of response to therapy is also reviewed in detail.

show abstract

Section: Differentiation Of Tumor Recurrence Versus Radiation Injurymentioning

confidence: 98%

11C-l-Methionine Positron Emission Tomography in the Clinical Management of Cerebral Gliomas

et al. 2007

View full text Add to dashboard Cite

show abstract

“…Tang et al [11] concluded that 11 C- L -methionine is a sensitive technique for the detection of recurrent adenoma tissue and, complementary to MRI, should gain a place in the efficient management of these tumors [12]. Several other groups have underlined the value of PET in the diagnosis and management of intracranial tumors including pituitary adenomas [13,14,15,16,17].…”

Section: Discussionmentioning

confidence: 99%

“…The results of scintigraphy with 123 I-methoxybenzamide ( 123 I-IBZM) [11] showed a somewhat varying correlation between the number of D 2 receptors identified in different types of pituitary adenomas and the response to dopamine agonist treatment [22,23,24,25]. For the GH adenomas in some of these materials, no significant uptake of 123 I-IBZM was identified, although sensitivity to quinagolide was found in some of the same GH adenomas.…”

Section: Discussionmentioning

confidence: 99%

Positron Emission Tomography in Acromegaly and Other Pituitary Adenoma Patients

Muhr¹

2006

Neuroendocrinology

View full text Add to dashboard Cite

Background: Positron emission tomography (PET) is a well-recognized technique used in research, especially for intracranial studies, as well as for clinical practice, and has contributed to the fast development in neuroscience during the last decades. Procedures: We have used PET in pituitary tumors for in vivo characterization with respect to metabolism, ¹¹C-L-methionine and ¹⁸F-fluorodeoxyglucose, receptor properties, ¹¹C-N-methylspiperone and ¹¹C-raclopride, and monoamine oxidase B enzyme content, ¹¹C-L-deprenyl; further, for diagnosing and outlining the tumors in differential diagnostic perspectives and in the follow-up of treatment. Observations:¹¹C-raclopride, a specific dopamine antagonist, demonstrated high amounts of dopamine D₂ binding in prolactinomas and some growth hormone-secreting adenomas. There was a significant correlation between high amounts of D₂ receptors and the positive treatment effect of dopamine agonist therapy. When ¹¹C-L-methionine and ¹⁸F-fluorodeoxyglucose were used for metabolic mapping, the highest metabolic activity was found in the prolactinomas, which correlated well with the serum prolactin levels. The growth hormone adenomas also showed high metabolic rates. At treatment follow-up, a considerable decrease in ¹¹C-L-methionine uptake was observed in all tumors that responded positively to the treatment and thus foretold that the medical treatment, both concerning dopamine agonist and somatostatin analogue, was effective. In this respect, PET was valuable to monitor treatment. PET was also shown valuable in differential diagnosing between pituitary adenomas, meningiomas and skull base neuromas. Conclusion: We have found PET to be highly valuable in the research and clinical handling of patients with a pituitary adenoma for in vivo tumor characterization.

show abstract

“…octreotide scintigraphy, 18 F-fluorodeoxyglucose positron emission tomography ( 18 F-FDG-PET)) has been employed by some workers, but with variable success, which in part reflects the limited spatial resolution of traditional scintigraphy and pituitary CT and the relatively high background uptake of 18 F-FDG by normal brain tissue. 11 C-methionine has been proposed as an alternative PET tracer for the localisation of pituitary adenomas (11,12). In contrast to 18 F-FDG, it is preferentially taken up by the normal pituitary gland, with relatively low uptake by the surrounding brain.…”

Section: Introductionmentioning

confidence: 99%

A role for 11C-methionine PET imaging in ACTH-dependent Cushing's syndrome

Koulouri

Steuwe

Gillett

et al. 2015

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: We report our experience of functional imaging with 11 C-methionine positron emission tomography-computed tomography (PET-CT) co-registered with 3D gradient echo (spoiled gradient recalled (SPGR)) magnetic resonance imaging (MRI) in the investigation of ACTH-dependent Cushing's syndrome. Design: Twenty patients with i) de novo Cushing's disease (CD, nZ10), ii) residual or recurrent hypercortisolism following first pituitary surgery (Gradiotherapy; nZ8) or iii) ectopic Cushing's syndrome (nZ2) were referred to our centre for functional imaging studies between 2010 and 2015. Six of the patients with de novo CD and five of those with persistent/relapsed disease had a suspected abnormality on conventional MRI. Methods: All patients underwent 11 C-methionine PET-CT. For pituitary imaging, co-registration of PET-CT images with contemporaneous SPGR MRI (1 mm slice thickness) was performed, followed by detailed mapping of 11 C-methionine uptake across the sella in three planes (coronal, sagittal and axial). This allowed us to determine whether suspected adenomas seen on structural imaging exhibited focal tracer uptake on functional imaging. Results: In seven of ten patients with de novo CD, asymmetric 11 C-methionine uptake was observed within the sella, which co-localized with the suspected site of a corticotroph microadenoma visualised on SPGR MRI (and which was subsequently confirmed histologically following successful transsphenoidal surgery (TSS)). Focal 11 C-methionine uptake that correlated with a suspected abnormality on pituitary MRI was seen in five of eight patients with residual or recurrent Cushing's syndrome following first TSS (and pituitary radiotherapy in two cases). Two patients elected to undergo repeat TSS with histology confirming a corticotroph tumour in each case. In two patients with the ectopic ACTH syndrome, 11 C-methionine was concentrated in sites of distant metastases, with minimal uptake in the sellar region. Conclusions:11 C-methionine PET-CT can aid the detection of ACTH-secreting tumours in Cushing's syndrome and facilitate targeted therapy.

show abstract

11C-methionine PET for the diagnosis and management of recurrent pituitary adenomas

Abstract: We suggest that MET-PET is a sensitive technique complementary to MRI for the detection of residual or recurrent pituitary adenomas. It should gain a place in the efficient management of these tumours.

Cited by 57 publications

References 40 publications

11C-l-Methionine Positron Emission Tomography in the Clinical Management of Cerebral Gliomas

11C-l-Methionine Positron Emission Tomography in the Clinical Management of Cerebral Gliomas

Positron Emission Tomography in Acromegaly and Other Pituitary Adenoma Patients

A role for 11C-methionine PET imaging in ACTH-dependent Cushing's syndrome

Contact Info

Product

Resources

About